Observational studyIrish journal of medical science2026
Glycaemic benefits of smart insulin pens in socioeconomically deprived individuals: a single-Centre study.
Observational study in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in diabetes technologies, disparities in access and uptake persist across socioeconomic and ethnic groups, further exacerbating health inequalities. Smart insulin pens (SIPs) are a cost-effective and accessible technology that provide insights into insulin dosing frequency and adherence patterns.
aimsTo evaluate the impact of SIP use on glycaemic outcomes in individuals with diabetes from predominantly socioeconomically deprived backgrounds.
methodsWe conducted a retrospective, single-centre observational study of 42 adults prescribed NovoPen® 6 or NovoPen Echo® Plus. Demographic, clinical, glycaemic and insulin dosing metrics were analysed. Socioeconomic status (SES) was assessed using the Pobal Deprivation Index. Outcomes were evaluated at baseline and follow-up.
resultsThe median age was 56.0 years (IQR 37.0–64.0), 22 participants (52.4%) were female, 28 (66.7%) had type 1 diabetes mellitus, and mean baseline HbA1c was 89.3 mmol/mol (±20.2). Most participants (68.3%) were in lower to middle SES categories. After a median follow-up of 16 weeks (IQR 8.3–30.0), SIP use was associated with improvements in glycaemic metrics including mean time in range (8.9%, p = 0.02), time above range (−9.6%, p = 0.04), and HbA1c (−7.7 mmol/mol, p = 0.01). No association was observed between SES and glycaemic outcomes.
conclusionsIn this socioeconomically disadvantaged cohort, SIPs were associated with improved glycaemic outcomes, suggesting they may represent an accessible alternative to more complex diabetes technologies. Further studies are needed to confirm long-term effectiveness, assess cost-effectiveness, and explore integration with digital health platforms.
Indexed as
Identifiers
41615565What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.